Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma (NAMS) Interest & Investment Income (2023 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Interest & Investment Income for 3 consecutive years, with $6.5 million as the latest value for Q4 2025.

  • Quarterly Interest & Investment Income rose 44.33% to $6.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27.6 million through Dec 2025, up 63.45% year-over-year, with the annual reading at $27.6 million for FY2025, 63.45% up from the prior year.
  • Interest & Investment Income hit $6.5 million in Q4 2025 for NewAmsterdam Pharma, down from $6.7 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $7.4 million in Q1 2025 to a low of $943000.0 in Q1 2023.
  • Historically, Interest & Investment Income has averaged $4.6 million across 3 years, with a median of $4.5 million in 2023.
  • Biggest YoY gain for Interest & Investment Income was 226.94% in 2024; the steepest drop was 5.57% in 2024.
  • Year by year, Interest & Investment Income stood at $2.7 million in 2023, then soared by 68.1% to $4.5 million in 2024, then surged by 44.33% to $6.5 million in 2025.
  • Business Quant data shows Interest & Investment Income for NAMS at $6.5 million in Q4 2025, $6.7 million in Q3 2025, and $7.1 million in Q2 2025.